New Customers Get 10% Off – Use Code: LUX10

Metabolic Peptide Agonist

GLP-3 (RT)

5.0 Reviews

BlendsGLP-3Research chemicals

A multi-receptor peptide agonist that targets GLP-1, GIP, and glucagon pathways, studied for its effects on metabolic regulation, energy balance, and weight management in clinical research. Premium Research Compound.

Price range: $71.99 through $242.99

2 Day FAST Shipping

99%+ Purity Tests

Ships from USA

USA Lab Tested

We accept :

Certificate of Analysis

Third Party Tested by Freedom Diagnostics

How GLP-3 (RT) Works

The Science, Simplified

The "Triple G" Mechanism

GLP-3 (RT) is a synthetic 39-amino acid peptide that activates three different nutrient-stimulated hormone receptors: GLP-1 (Glucagon-like peptide-1), GIP (Glucose-dependent insulinotropic polypeptide), and GCGR (Glucagon receptor).
Key insight: Most current treatments target one or two of these receptors. By adding the Glucagon receptor (GCGR), GLP-3 (RT) doesn’t just suppress appetite; it directly increases energy expenditure and targets fat stored in the liver. In Phase 3 trials, researchers observed an average weight loss of 28.7% (about 71 lbs) at the highest dose over 68 weeks.
GE
Primary

Gene Expression

Epigenetic Modulation

Upregulates 59% of affected genes Activates 47 DNA repair genes Suppresses inflammatory pathways

COL
Strongest

Gene Expression

Epigenetic Modulation

Upregulates 59% of affected genes Activates 47 DNA repair genes Suppresses inflammatory pathways

Cu²⁺
Supportive

Gene Expression

Epigenetic Modulation

Upregulates 59% of affected genes Activates 47 DNA repair genes Suppresses inflammatory pathways

Direct Fat Oxidation & Liver Clearance

The glucagon component is often called the "secret weapon" of this compound because it signals the body to burn fat for energy more aggressively.

Key insight: In clinical research, this triple-action approach led to a staggering 86% reduction in liver fat, with 93% of participants reaching normal liver fat levels. This makes it a primary subject for studies involving MASH (Metabolic dysfunction-associated steatohepatitis) and other fatty liver conditions.

Superior Glycemic & Appetite Control

GLP-3 (RT) slows gastric emptying and improves insulin sensitivity more effectively than dual-receptor agonists.

Key insight: Research shows it can reverse prediabetes in up to 72% of participants, returning them to normal blood sugar levels. Its ability to “rewire” hunger cues at a deeper level has led to nearly 4 in 10 participants losing 30% or more of their body weight—results previously seen only with invasive surgery.

Wrinkle Reduction Comparison

Safety Profile from Research

What clinical studies report

GLP-3 (RT) is currently in Phase 3 clinical trials (the "TRIUMPH" program). While highly effective, its triple-action potency requires careful observation in a research setting.

🧿 Common Digestive Issues

43%

Nausea

mild

20.9%

Dysesthesia

mild

33%

Diarrhea

mild

Safety Advantage

Non-Suppressive Elevation

📊 Discontinuation Rates

🚫 Trial Exclusions

⚡ Regulatory Status

💡 Researcher Notes

Compound Information

Technical specifications for this 39aa triple agonist

🔬 Molecular Profile

What Is Retatrutide?

Full Name

GLP-3 (RT) / Retatrutide

CAS Number

2381089-83-2

Molecular Weight

4,731.33 g/mol

Structure

39-Amino Acid Peptide

Purity

≥99%

🧊 Storage Requirements

Stability Information

Lyophilized (powder)

-20°C

24+ months

Reconstituted

2-8°C

~30 days

Handling

Avoid light and heat;

do not shake after adding solvent.

📋Research Status

Development History

Clinical Stage

Phase III (TRIUMPH Program)

Classification

Triple Incretin Agonist

Primary Goal

Obesity, NAFLD/MASH, Type 2 Diabetes

US Status

Investigational Research Compound

Frequently Asked Questions

Common questions about GLP-3 (RT)

Semaglutide targets one receptor (GLP-1), and Tirzepatide targets two (GLP-1 + GIP). GLP-3 (RT) targets three (GLP-1 + GIP + Glucagon). This third receptor is why researchers see significantly higher weight loss percentages and faster liver fat reduction compared to earlier generations.
In clinical research, "titration" is vital to minimize side effects. Researchers typically start with the vial to assess tolerance. Higher doses like the or options are used in later stages of the protocol to maximize the metabolic response.
This sensation, known as dysesthesia, was reported by about 20% of participants in the highest-dose trials. It is usually described as mild and temporary. Researchers believe it is a direct effect of the glucagon receptor interacting with sensory pathways, but it generally does not require stopping the research protocol.
Data from the Phase 2 trials showed that an incredible 93% of participants who had fatty liver disease returned to a "normal" liver fat range (under 5%) after 48 weeks of research.
No. It is still in active Phase 3 clinical trials, with results expected in 2026. It is currently sold strictly as an investigational research compound and is not approved for human consumption.

Sources & References

Peer-reviewed research

Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.

All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.

By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.